Neurology News and Research

Latest Neurology News and Research

Laquinimod drug greatly reduces number of relapses in patients with MS

The drug laquinimod reduced the number of relapses for people with multiple sclerosis, in a large, long-term Phase III clinical study that will be presented as late-breaking research at the 63rd Annual Meeting of the American Academy of Neurology, April 9-16, 2011, in Honolulu.

12 Apr 2011

New guideline on most effective treatments for diabetic nerve pain

The American Academy of Neurology has issued a new guideline on the most effective treatments for diabetic nerve pain, the burning or tingling pain in the hands and feet that affects millions of people with diabetes. The guideline is published in the April 11, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology, and will be presented April 11, 2011, at the American Academy of Neurology's Annual Meeting in Honolulu.

12 Apr 2011

Epilepsy medication USL255 associated with less fluctuation in plasma levels compared to topiramate IR

Upsher-Smith Laboratories today announced the presentation of data indicating that once daily administration of USL255, a proprietary extended-release (ER) formulation of the epilepsy medication topiramate, was associated with less fluctuation in topiramate plasma levels compared to immediate-release (IR) topiramate administered twice daily in healthy volunteers.

12 Apr 2011

REACH introduces new web-based services for physicians

REACH Health, Inc., a leading provider of comprehensive clinical telemedicine solutions, today announced that it has launched REACH Physician Services for Tele-Stroke, Tele-Neurology and Tele-ICU call coverage.

12 Apr 2011

Alzheimer’s drug – a failure of sorts: Study

Results from the study shows that drug, memantine, is no better than a dummy pill when it comes to ameliorating disease symptoms, including the decline of mental abilities and also helping patients with moderate Alzheimer's, the researchers say. Sold under the brand Namenda by Forest Laboratories Inc and Germany's Merz Pharma, the drug had U.S. sales of about $1.2 billion last year.

11 Apr 2011

Neurosurgeons to present techniques and discuss surgical approaches at AANS meeting

Neurosurgeons from NYU Langone Medical Center will present techniques and discuss surgical approaches and applications of technology at the annual meeting of the American Association of Neurological Surgeons, held April 9-13, 2011 at the Colorado Convention Center in Denver.

11 Apr 2011

Annals of Neurology publishes Diamyd Medical´s NP2 Enkephalin Phase I results in cancer pain

Diamyd Medical´s Phase I clinical trial results evaluating the safety and efficacy of the candidate drug NP2 Enkephalin to treat intractable cancer pain has been published in the medical journal Annals of Neurology.

11 Apr 2011

Gilenya can reduce risk of disability progression in patients with RRMS

A new analysis demonstrated that Gilenya reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology.

11 Apr 2011

Air pollution on freeways may lead to brain damage: Study

Earlier research has shown that air pollution from cars and trucks on Southern California freeways – that contains soot, pavement dust and other toxic substances - can cause respiratory disease, heart attacks, cancer and premature death. Now a new study has shown that exposure to pollution particles roughly one-thousandth the width of a human hair may lead to brain damage in mice, including signs associated with memory loss and Alzheimer’s disease. The study comes from University of Southern California and is published in the journal Environmental Health Perspectives.

10 Apr 2011

New publication on therapeutic hypothermia and temperature management

The successful use and evaluation of therapeutic hypothermia to improve survival and reduce the risk of neurological consequences following an out-of-hospital heart attack are explored in the premier issue of Therapeutic Hypothermia and Temperature Management, a new quarterly peer-reviewed journal published by Mary Ann Liebert, Inc.

8 Apr 2011

GlaxoSmithKline, XenoPort receive FDA approval for Horizant to treat RLS

On April 6, the U.S. Food and Drug Administration approved Horizant Extended Release Tablets, a once-daily treatment for moderate-to-severe restless legs syndrome.

8 Apr 2011

Antidepressant medication improves physical recovery from stroke

A University of Iowa study finds that patients treated with a short course of antidepressants after a stroke have significantly greater improvement in physical recovery than patients treated with a placebo. Moreover, the study is the first to demonstrate that this physical recovery continues to improve for at least nine months after the antidepressant medication is stopped.

8 Apr 2011

NAFC honors UT Southwestern nurse with Continence Care Champion Award

The National Association For Continence presented Tamara Dickinson, RN, CURN, CCCN, BCB-PMD, with its Rodney Appell Continence Care Champion Award at the Society of Urologic Nurses and Associates luncheon on March 11, held during the 2011 SUNA Annual Symposium in New Orleans.

8 Apr 2011

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

Genzyme, a subsidiary of sanofi-aventis Group, announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis at the American Academy of Neurology's 63rd Annual Meeting in Hawaii, April 9 - 16, 2011.

8 Apr 2011

Study: DBS surgery allows 77% of patients to stop anti-tremor medication use

Deep brain stimulation, a surgical procedure to suppress faulty nerve signals, allowed 77 percent of patients to stop the medications used to treat their essential tremors within one year following the surgery, University of South Florida researchers report.

8 Apr 2011

Patients with stroke can benefit from antidepressants

8 Apr 2011

Meditation can conquer pain: Well almost!

Meditation can be used as a powerful painkiller says new research published in the Journal of Neuroscience. The study from Wake Forest Baptist Medical Center showed as much reflected in perception of the participants as well as their brain scans.

7 Apr 2011

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.

7 Apr 2011

MAP Pharma publishes LEVADEX Phase 3 FREEDOM-301 study data in 'Headache' journal

MAP Pharmaceuticals, Inc. today announced the publication of results from the Phase 3 FREEDOM-301 study of LEVADEX orally inhaled migraine drug in the peer-reviewed journal 'Headache.'

7 Apr 2011

Neuralstem to present HSSC Phase I trial data in amyotrophic lateral sclerosis at AAN meeting

Neuralstem, Inc. announced that the Phase I safety trial of its human spinal cord stem cells in amyotrophic lateral sclerosis is the subject of three presentations at the American Academy of Neurology Annual Meeting, April 9-16th, in Honolulu, HI.

7 Apr 2011